NB: None for Omadacycline yet, at least in EUCAST.
| Resistance mechanism | Tigecycline | Eravacycline | Omadacycline |
|---|---|---|---|
| Efflux pumps | Little to none |
Enterococcus: MFS pump
Gm negs: RND (AdeABC, AdeFGH, AdeIJK, MexXY, and AcrAB) | Little to none
Reports of MDR efflux pumps | Little to none | | Ribosomal protection protein | Enterococcus: tet(M) | | Little to none | | Drug degradation (Aerobes only) | | | | | rRNA mutation | | Reported | Reported |
| Resistance mechanism | Tigecycline | Eravacycline | Omadacycline |
|---|---|---|---|
| ESBL | Can use, unless BSI/UTI | Can use, unless BSI/UTI | Can use but limited data, Avoid in BSI |
| CRE | Can use, unless BSI/UTI | Can use, unless BSI/UTI | Avoid |
| CRAB | Use in combination | Use if no other option available | Avoid |
| S.maltophilia | Can use, unless UTI | Can use, unless UTI | Avoid |
Tigecycline or eravacycline can be considered as alternative options for intra-abdominal infections, SSTI, osteomyelitis, and respiratory infections